Table 5 Annual country-level net budget impact
Block Depth At Reversal | Prior NMBA & Reversal Agent | Prior Scenario Drug Costs | Alternative Scenario (incl. sugammadex) Drug Costs | Total Cost Offsets From Clinical Events Avoided | Net Cost Savings |
|---|---|---|---|---|---|
Moderate | Rocuronium + No reversal | €212,903 | €6,272,453 | €36,308,198 | -€30,248,647 |
Moderate | Rocuronium + Neostigmine | €184,369 | €4,321,505 | €25,015,106 | -€20,877,969 |
Deep | Rocuronium + No reversal | €53,225 | €3,083,001 | €9,077,049 | -€6,047,274 |
Total Budget Impact | €450,498 | €13,676,960 | €70,400,354 | -€57,173,892 |